NCT07829809Not yet recruiting
Serum Adropin as an Indicator of Endothelial Dysfunction and Disease Severity in Obstructive Sleep Apnea in Obese Patients
Source: ClinicalTrials.gov · Last updated 21 Sept 2026
Brief summary (registry, in English)
1\. Objectives (Aim): To evaluate the role of serum adropin as a potential biomarker of endothelial dysfunction in OSA 1. Compare serum adropin levels between Obese patients with and without OSA. 2. Correlate serum adropin with OSA severity indices including the Apnea-Hypopnea Index (AHI) and Oxygen Desaturation Index (ODI) and cardiovascular complications. 3. Assess the relationship between serum adropin and endothelial dysfunction markers (endothelin-1). 4. Evaluate adropin's predictive ability for endothelial impairment among OSA patients.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 80 (estimated)
- First submitted
- 15 Sept 2026
- Start date
- 15 Sept 2026
- Primary completion date
- 1 Sept 2027
- Lead sponsor
- Aswan University
- Diseases
- Obesity
- NCT number
- NCT07829809
What you commit to
- Study type: Observational
- Planned participants: 80
- From 15 Sept 2026 to the primary completion date, 1 Sept 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- 1-Pregnant females 2-Thyroid disorders 3-Autoimmune diseases 4-chronic liver disease 5-chronic kidney disease 6-drugs as statin,glucocorticoids and antidepressant
Who the study is looking for
- 1- Adults aged 20-75 years. 2-obese Patients diagnosed with obstructive sleep apnea (OSA) confirmed by polysomnography.
- 3- Patients willing to provide written informed consent. 4- Patients not currently on medications affecting endothelial function (e.g., statins, ACE inhibitors) or able to temporarily withhold under medical supervision.
- 5- Ability to comply with study procedures and follow-up
Age in the registry: 20 years to 75 years · Sex: All · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.